{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:24:45Z","timestamp":1791224685959,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:00:00Z","timestamp":1570147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We tested the hypothesis that using CXCR4 inhibition to target the interaction between the tumor cells and the microenvironment leads to sensitization of the tumor cells to apoptosis. Eligibility criteria included multiple myeloma (MM) patients with 1\u20105 prior lines of therapy. The purposes of the phase I study were to evaluate the safety and maximal\u2010tolerated dose (MTD) of the combination. The treatment\u2010related adverse events and response rate of the combination were assessed in the phase II study. A total of 58 patients were enrolled in the study. The median age of the patients was 63\u2009years (range, 43\u201085), and 78% of them received prior bortezomib. In the phase I study, the MTD was plerixafor 0.32\u2009mg\/kg, and bortezomib 1.3 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    . The overall response rate for the phase II study was 48.5%, and the clinical benefit rate 60.6%. The median disease\u2010free survival was 12.6 months. The CyTOF analysis demonstrated significant mobilization of plasma cells, CD34+ stem cells, and immune T cells in response to plerixafor. This is an unprecedented study that examines therapeutic targeting of the bone marrow microenvironment and its interaction with the tumor clone to overcome resistance to therapy. Our results indicate that this novel combination is safe and that the objective response rate is high even in patients with relapsed\/refractory MM.\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                    , NCT00903968.\n                  <\/jats:p>","DOI":"10.1002\/ajh.25627","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T02:29:40Z","timestamp":1566959380000},"page":"1244-1253","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Phase I\/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed\/refractory multiple myeloma"],"prefix":"10.1002","volume":"94","author":[{"given":"Irene M.","family":"Ghobrial","sequence":"first","affiliation":[{"name":"Medical Oncology, Dana\u2010Farber Cancer Institute Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia\u2010Jen","family":"Liu","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana\u2010Farber Cancer Institute Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana","family":"Zavidij","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana\u2010Farber Cancer Institute Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6371-2780","authenticated-orcid":false,"given":"Abdel K.","family":"Azab","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana\u2010Farber Cancer Institute Harvard Medical School  Boston Massachusetts"},{"name":"Department of Radiation Oncology Cancer Biology Division, Washington University School of Medicine  St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4538-4733","authenticated-orcid":false,"given":"Rachid","family":"Baz","sequence":"additional","affiliation":[{"name":"Department of Malignant Haematology H. Lee Moffitt Cancer Center and Research Institute  Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Laubach","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana\u2010Farber Cancer Institute Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Mishima","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana\u2010Farber Cancer Institute Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana\u2010Farber Cancer Institute Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana\u2010Farber Cancer Institute Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Basile","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Davenport\u2010Mugar Cancer Center, Cape Cod Hospital  Hyannis Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Constantine","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber\/Brigham and Women's Cancer Center, Milford Regional Medical Center  Milford Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Vredenburgh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Saint Francis Hospital and Medical Center  Hartford Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Boruchov","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Saint Francis Hospital and Medical Center  Hartford Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Crilley","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Cancer Treatment Centers of America, Eastern Regional Medical Center  Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Henrick","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana\u2010Farber Cancer Institute Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3361-6560","authenticated-orcid":false,"given":"Kalvis T. V.","family":"Hornburg","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana\u2010Farber Cancer Institute Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houry","family":"Leblebjian","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana\u2010Farber Cancer Institute Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Chuma","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana\u2010Farber Cancer Institute Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlen","family":"Reyes","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana\u2010Farber Cancer Institute Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Noonan","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana\u2010Farber Cancer Institute Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Warren","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana\u2010Farber Cancer Institute Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schlossman","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana\u2010Farber Cancer Institute Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Paba\u2010Prada","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana\u2010Farber Cancer Institute Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana\u2010Farber Cancer Institute Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edie","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology Dana\u2010Farber Cancer Institute  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Trippa","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology Dana\u2010Farber Cancer Institute  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Shain","sequence":"additional","affiliation":[{"name":"Department of Malignant Haematology H. Lee Moffitt Cancer Center and Research Institute  Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana\u2010Farber Cancer Institute Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,10,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.122"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.196"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.05.005"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1926"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-525808"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-035857"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3394"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-185827"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-186668"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.336"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.1.435"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.4.2357"},{"key":"e_1_2_9_19_1","first-page":"e4398","article-title":"Mass cytometry: protocol for daily tuning and running cell samples on a CyTOF mass cytometer","volume":"69","author":"Leipold MD","year":"2012","journal-title":"J Vis Exp"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2014.10.010"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/35065016"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.462"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.07.131"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705908"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.130"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05519.x"},{"key":"e_1_2_9_28_1","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study","volume":"91","author":"Harousseau JL","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70440-1"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25627","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.25627","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25627","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T09:34:16Z","timestamp":1694079256000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.25627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,4]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1002\/ajh.25627"],"URL":"https:\/\/doi.org\/10.1002\/ajh.25627","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,4]]},"assertion":[{"value":"2019-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}